Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-01-26
2010-10-26
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S085200, C424S134100, C514S002600
Reexamination Certificate
active
07820167
ABSTRACT:
Diagnostic methods for the detection of multiple myeloma (MM) and the identification of high-risk patients with multiple myeloma-related plasma proliferative disorders, such as MGUS or SMM, likely to progress to active MM are described. The diagnosis is based on the determination of concentrations of bioactive IL-1β produced by the bone marrow plasma cells of these patients. Also described are therapeutic methods for the treatment of MM and for the chemoprevention of the progression from disorders such as MGUS and SMM to active MM, involving the administration of inhibitors of IL-1β.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5470952 (1995-11-01), Stahl et al.
patent: 5844099 (1998-12-01), Stahl et al.
patent: WO 98/03657 (1998-01-01), None
Lust et al., “Interleukin-1 receptor antagonist (IL-1Ra) targets the proliferative component in early stage myeloma,”Blood(ASH Annual Meeting Abstracts), 2004, 104:Abstract 2412.
Lust et al., “Clinical and biologic studies in smoldering/indolent multiple myeloma (SMM/IMM) suggest that therapies that specifically inhibit IL-6 production are more effective at targeting the proliferative myeloma component than apoptosis inducing agents,”Blood(ASH Annual Meeting Abstracts), 2006, 108:Abstract 3500.
Lust et al., “Prevention of active multiple myeloma (MM) using IL-1 receptor anatagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP),”J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (Jun. 20 Supplement), 2007:Abstract 8105.
Famularo et al., “The role of cytokines in the pathogenesis of monoclonal gammapathies,”EOS-Rivista Di Immunologia Ed Immunofarmacologia, 1993, 13:176-185, Abstract only.
Wallace et al., “Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients,”Cancer, 2001, 91(7):1219-1230, Abstract only.
Vacca et al., “A Disturbance of the IL-2-IL-2 Receptor System Parallels the Activity of Multiple Myeloma,”Clin. Exp. Immunol., 1991, 84(3):429-434, Abstract only.
“Human Interleukin-6 UltraSensitive (hIL-6 US) ELISA Kit,” Summary Protocol, BioSource International, Inc., pp. 1-2.
Alexanian and Dimopoulos, “The Treatment of Multiple Myeloma,”New Engl. J. Med., 1994, 330(7):484-489.
Attal et al., “A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma,”N. Engl. J. Med., 1996, 335:91-97.
Bataille et al., “Clinical Evaluation of Response or Escape to Chemotherapy and of Survival of Patients with Multiple Myeloma. A Prospective Study of 202 Patients (1975-1982),”Anticancer Research, 1984, 4:339-346.
Bataille et al., “Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias,”J. Clin. Invest., 1989, 84:2008-2011.
Bataille et al., “Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma,”Blood, 1995, 86(2):685-691.
Borset et al., “Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation,”Br. J. Haematology, 1993, 85:446-451.
Carter et al., “The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma,”Br. J. Haematol., 1990, 74:424-431.
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,”Nature, 1990, 344:633-638.
Chauhan et al., “Multiple Myeloma Cell Adhesion-Induced Interleukin-6 Expression in Bone Marrow Stromal Cells Involves Activation of NF-κB,”Blood, 1996, 87(3):1104-1112.
Choi et al., “Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma,”Blood, 2000, 96(2):671-675.
Cole et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,”Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, pp. 77-96.
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,”Proc. Natl. Acad. Sci. USA, 1983, 80:2026-2030.
Costes et al., “Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production,”Br. J. Haematol., 1998, 103:1152-1160.
Cytokines: A Practical Approach, 1991, Balkwill (ed.), Oxford University Press, pp. 311-312.
Dankbar et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma,”Blood, 2000, 95(8):2630-2636.
Dinarello et al., “Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome,”JAMA, 1993, 269(14):1829-1835.
Dinarello, “Biologic Basis for Interleukin-1 in Disease,”Blood, 1996, 87(6):2095-2147.
Dinarello and Thompson, “Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro,”Immunol. Today, 1991, 12(11):404-410.
Donovan et al., “Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma,”Leukemia, 1998, 12:593-600.
Donovan et al., “Stromal Cell Interleukin-6 (IL-6) Production and Percent Plasma Cells Predict Progression of Smoldering Multiple Myeloma (SMM) to Multiple Myeloma (MM): Importance of the IL-1β/IL-6 Axis in Myeloma Pathogenesis,”44thASH Annual Meeting, 2002, 2 pages.
Eisenberg et al., “Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist,”Nature, 1990, 343:341-346.
Fingl and Woodbury, “General Principles,”The Pharmaceutical Basis of Therapeutics, 1975, MacMillan Publishing Co., New York, Chapter 1, pp. 1-46.
Greipp and Lust, “Pathogenetic Relation Between Monoclonal Gammopathies of Undetermined Significance and Multiple Myeloma,”Stem Cells, 1995, 13(Suppl. 2):10-21.
Greipp and Witzig, “Biology and treatment of myeloma,”Curr. Opn. Oncol., 1996, 8:20-27.
Grigorieva et al., “The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone,”Exp. Hematol., 1998, 26:597-603.
Hannum et al., “Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor,”Nature, 1990, 343:336-340.
Hawley et al., “Expression of Retrovirally Transduced IL-1αin IL-6-Dependent B Cells: A Murine Model of Aggressive Multiple Myeloma,”Growth Factors, 1991, 5:327-338.
Hilbert et al., “Interleukin 6 Is Essential for In Vivo Development of B Lineage Neoplasms,”J. Exp. Med., 1995, 182:243-248.
Howard et al., “IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the IL-1β Precursor at Two Distinct Sites and Does Not Cleave 31-kDa IL-1α,”J. Immunol., 1991, 147(9):2964-2969.
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science, 1989, 246:1275-1281.
Kawano et al., “Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas,”Nature, 1988, 332:83-85.
Kishimoto, “The Biology of Interleukin-6,”Blood, 1989, 74:1-10.
Kiss et al., “Determination of IL6, Ill and IL4 in the Plasma of Patients with Multiple Myeloma,” Leukemia and Lymphoma, 1994, 14:335-340.
Klein et al., “Paracrine Rather Than Autocrine Regulation of Myeloma-Cell Growth and Differentiation by Interleukin-6,”Blood, 1989, 73(2):517-526.
Klein et al., “Inhibiting IL-6 in Human Multiple Myeloma,”Curr. Topics Microbiol. Immunol., 1992, 182:237-244.
Köhler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 1975, 256:495-497.
Kozbor and Roder, “The production of monoclonal antibod
Donovan Kathleen A.
Lust John A.
Fish & Richardson P.C.
Hill Myron G
Mayo Foundation for Medical Education and Research
Mosher Mary E
LandOfFree
IL1-β: a new target for myeloma therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL1-β: a new target for myeloma therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL1-β: a new target for myeloma therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220089